RPRX Royalty Pharma plc

Price (delayed)

$36.81

Market cap

$22.35B

P/E Ratio

14.78

Dividend/share

$0.66

EPS

$2.49

Enterprise value

$27.03B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
RPRX's equity has surged by 150% year-on-year and by 6% since the previous quarter
Royalty Pharma's EPS has surged by 66% QoQ
The net income has plunged by 59% YoY

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
607.17M
Market cap
$22.35B
Enterprise value
$27.03B
Valuations
Price to earnings (P/E)
14.78
Price to book (P/B)
2.15
Price to sales (P/S)
6.73
EV/EBIT
24.23
EV/EBITDA
24.23
EV/Sales
12.08
Earnings
Revenue
$2.24B
EBIT
$1.12B
EBITDA
$1.12B
Free cash flow
$2.11B
Per share
EPS
$2.49
Free cash flow per share
$5.16
Book value per share
$17.14
Revenue per share
$5.47
TBVPS
$40.3
Balance sheet
Total assets
$16.51B
Total liabilities
$6.11B
Debt
$5.83B
Equity
$10.41B
Working capital
$2.42B
Liquidity
Debt to equity
0.56
Current ratio
9.53
Quick ratio
9.49
Net debt/EBITDA
4.2
Margins
EBITDA margin
49.8%
Gross margin
100%
Net margin
43.4%
Operating margin
80.4%
Efficiency
Return on assets
6%
Return on equity
11.2%
Return on invested capital
5.4%
Return on capital employed
6.9%
Return on sales
49.8%
Dividend
Dividend yield
1.79%
DPS
$0.66
Payout ratio
26.5%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-2.46%
1 week
-1.55%
1 month
-0.92%
1 year
-2.8%
YTD
-26.45%
QTD
1.85%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.24B
Gross profit
$2.24B
Operating income
$1.8B
Net income
$971.62M
Gross margin
100%
Net margin
43.4%
Royalty Pharma's net margin has shrunk by 64% YoY and by 2% QoQ
The net income has plunged by 59% YoY
The operating margin has declined by 41% year-on-year but it has increased by 21% since the previous quarter
The operating income has contracted by 32% YoY but it has grown by 23% from the previous quarter

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
14.78
P/B
2.15
P/S
6.73
EV/EBIT
24.23
EV/EBITDA
24.23
EV/Sales
12.08
Royalty Pharma's EPS has surged by 66% QoQ
The P/E is 35% lower than the last 4 quarters average of 22.6
RPRX's equity has surged by 150% year-on-year and by 6% since the previous quarter
RPRX's P/B is 39% below its last 4 quarters average of 3.5
The revenue has increased by 16% YoY and by 2% from the previous quarter
The P/S is 16% below the last 4 quarters average of 8.0

Efficiency

How efficient is Royalty Pharma business performance
RPRX's ROE has plunged by 80% YoY and by 18% from the previous quarter
Royalty Pharma's return on sales has shrunk by 62% YoY
The ROIC has shrunk by 61% YoY and by 3.6% QoQ
The ROA has plunged by 60% YoY

Dividends

What is RPRX's dividend history
DPS
$0.66
Dividend yield
1.79%
Payout ratio
26.5%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 170% more than its total liabilities
The company's quick ratio rose by 27% YoY
The current ratio has increased by 27% year-on-year
Royalty Pharma's debt is 44% lower than its equity
RPRX's equity has surged by 150% year-on-year and by 6% since the previous quarter
The debt to equity has shrunk by 61% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.